Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data

Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data

Background: Little is known about disease trajectories for men with castration-resistant prostate cancer (CRPC). Objective: To create a state transition model that estimates time spent in the CRPC state and its outcomes. Design, setting, and participants: The model was generated using population-bas...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Eugenio Ventimiglia, Anna Bill-Axelson, Jan Adolfsson, Markus Aly, Martin Eklund, Marcus Westerberg, Pär Stattin, Hans Garmo
Formáid:	Alt
Teanga:	English
Foilsithe / Cruthaithe:	Elsevier 2022-10-01
Sraith:	European Urology Open Science
Ábhair:	Castration-resistant prostate cancer Survival State transition model
Rochtain ar líne:	http://www.sciencedirect.com/science/article/pii/S2666168322007406

Míreanna comhchosúla

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
de réir: Lixin Mai, et al.
Foilsithe / Cruthaithe: (2020-12-01)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
de réir: Magdalena Schrank, et al.
Foilsithe / Cruthaithe: (2020-01-01)

Experimental study of apoptosis in the prostate tissue following castration
de réir: Y Doustar, et al.
Foilsithe / Cruthaithe: (2008-02-01)

Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis
de réir: Kyo Chul Koo, et al.
Foilsithe / Cruthaithe: (2018-04-01)

Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer
de réir: Pascoe Abigail C, et al.
Foilsithe / Cruthaithe: (2012-03-01)

Ultrasonographic measurements of the prostate gland in castrated adult dogs
de réir: Femke Bosma, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs
de réir: Turco F, et al.
Foilsithe / Cruthaithe: (2022-09-01)

Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease
de réir: Bo-Ren Wang, et al.
Foilsithe / Cruthaithe: (2022-08-01)

Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study
de réir: Huanyi Lin, et al.
Foilsithe / Cruthaithe: (2021-04-01)

A drug comorbidity index to predict mortality in men with castration resistant prostate cancer.
de réir: Giuseppe Fallara, et al.
Foilsithe / Cruthaithe: (2021-01-01)

Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel
de réir: Koichi Uemura, et al.
Foilsithe / Cruthaithe: (2018-05-01)

Prognostic value of the HALP score in metastatic castration-resistant prostate cancer: an analysis combined with time to castration resistance
de réir: İvo Gökmen, et al.
Foilsithe / Cruthaithe: (2024-12-01)

Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
de réir: Caffo O, et al.
Foilsithe / Cruthaithe: (2016-12-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
de réir: T. N. Skvortsova, et al.
Foilsithe / Cruthaithe: (2017-01-01)

Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
de réir: Alexander W Wyatt, et al.
Foilsithe / Cruthaithe: (2015-04-01)

Association of Body Composition With Survival and Treatment Efficacy in Castration-Resistant Prostate Cancer
de réir: Sahyun Pak, et al.
Foilsithe / Cruthaithe: (2020-04-01)

Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review
de réir: Meagher MF, et al.
Foilsithe / Cruthaithe: (2023-11-01)

Novel Strategies for Treating Castration-Resistant Prostate Cancer
de réir: David Ka-Wai Leung, et al.
Foilsithe / Cruthaithe: (2021-03-01)

Mechanisms of castration resistant prostate cancer formation and progression through neuroendocrine differentiation
de réir: Xueping Ma, et al.
Foilsithe / Cruthaithe: (2021-09-01)

Enzalutamide Maintenance Following Docetaxel in Metastatic Castration-Naive Prostate Cancer: A Pilot Feasibility Study
de réir: Sung Hee Lim, et al.
Foilsithe / Cruthaithe: (2024-03-01)

Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice
de réir: Geehyun Song, et al.
Foilsithe / Cruthaithe: (2013-09-01)

Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy
de réir: Minyong Kang, et al.
Foilsithe / Cruthaithe: (2015-12-01)

Prostate-Specific Antigen and Time to PSA Nadir as Prognostic Significance in Castration-Resistant Prostate Cancer
de réir: Firmantya Hadi Pranata, et al.
Foilsithe / Cruthaithe: (2022-03-01)

Spontaneous Rectovesical Fistula Secondary to Castration-resistant Prostate Cancer
de réir: Okwudili Calistus Amu, et al.
Foilsithe / Cruthaithe: (2024-06-01)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
de réir: Mark N Stein, et al.
Foilsithe / Cruthaithe: (2014-06-01)

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
de réir: İlkay Gültürk, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Physician and Patient Preferences for the Treatment of Metastatic Castration-Sensitive and Castration-Resistant Prostate Cancer: A Best-Worst Scaling Study in Japan
de réir: Takahiro Kimura, et al.
Foilsithe / Cruthaithe: (2025-02-01)

Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer
de réir: Sahyun Pak, et al.
Foilsithe / Cruthaithe: (2022-09-01)

Bioinformatic Analysis of Potential Key Genes in Castration-resistant Prostate Cancer Development
de réir: DONG Jingting, HENG Li, KANG Shaosan, LIU Jian, TIAN Zhichong, ZHANG Liguo, ZHANG Jincun, LI Zhiguo, SHEN Hong, CAO Fenghong
Foilsithe / Cruthaithe: (2022-03-01)

PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China
de réir: Kai-Jie Wu, et al.
Foilsithe / Cruthaithe: (2018-01-01)

The role of glutamine metabolism in castration-resistant prostate cancer
de réir: Bing Zhao, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Contemporary Treatment Patterns and Oncological Outcomes of Metastatic Hormone-sensitive Prostate Cancer and First- to Sixth- line Metastatic Castration-resistant Prostate Cancer Patients
de réir: Mike Wenzel, et al.
Foilsithe / Cruthaithe: (2024-08-01)

The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance
de réir: Ao Liu, et al.
Foilsithe / Cruthaithe: (2023-09-01)

Oral etoposide and oral prednisone for the treatment of castration resistant prostate cancer
de réir: Yi-Ping Zhu, et al.
Foilsithe / Cruthaithe: (2014-02-01)

Efficacy and safety of Prostate stereotactic body radiotherapy for metastatic castration-resistant prostate cancer: A prospective cohort study
de réir: Jun Li, et al.
Foilsithe / Cruthaithe: (2021-01-01)

Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial
de réir: Byung Ha Chung, et al.
Foilsithe / Cruthaithe: (2023-01-01)

ALDH1A3 serves as a predictor for castration resistance in prostate cancer patients
de réir: Shangqian Wang, et al.
Foilsithe / Cruthaithe: (2020-05-01)

A COMPARISON OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS WITH THE USE OF ABIRATERONE ACETATE AND DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
de réir: A. V. Kondrashina, et al.
Foilsithe / Cruthaithe: (2018-05-01)

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate
de réir: España S, et al.
Foilsithe / Cruthaithe: (2020-10-01)

Current status and treatment direction of the immune microenvironment of castration-resistant prostate cancer
de réir: YANG Wenbo, ZHANG Bin, WU Jiahui, CUI Jie
Foilsithe / Cruthaithe: (2023-10-01)